Mucosal IgA against pre-fusion F protein predicts RSV protection

Respiratory syncytial virus, known widely as RSV, has long been thought of as a disease of infancy, yet its burden extends across the entire human lifespan, and nowhere is that burden more visible than in communities of the Gambia and other parts of West Africa, where RSV circulation is intense, seasonal peaks are pronounced, and the virus ranks among the leading causes of acute lower respiratory infection in infants and a substantial cause of severe disease in the elderly. A new study published in Nature Communications by Deborah Hodgson, Saydibatou Jarju, Lindsey Gatcombe and colleagues now offers what many in the field consider a decisive answer to a question that has shaped vaccine development for decades: which arm of the immune system actually predicts protection against RSV infection in a real-world, high-transmission setting. The answer, the researchers report, is not the abundant serum antibodies measured in most clinical trials, but a far less accessible player, immunoglobulin A at the mucosal surfaces of the respiratory tract, directed specifically against the pre-fusion conformation of the viral F protein.

The distinction matters enormously because RSV entry into human cells depends on its fusion, or F, glycoprotein, a molecule that exists on infectious virions in a metastable pre-fusion shape before snapping irreversibly into a post-fusion form after mediating membrane merger. The pre-fusion form, often abbreviated pre-F, displays the most vulnerable antigenic sites on the virus, including the highly sensitive site Ø that neutralizing antibodies target with the greatest potency. For years, vaccine designers have therefore tried to stabilize the pre-fusion conformation, an engineering triumph that underlies the maternal vaccine approved in recent years and the monoclonal antibodies now given to infants. Yet measuring the right antibody response in the right compartment has remained a stubborn blind spot. Serum, sampled easily from a vein, reflects systemic immunity, but RSV infects its host through the nasal and airway epithelium, the mucosa, where a different antibody class, dimeric secretory IgA, dominates and where immune exclusion of pathogens actually takes place.

The study, conducted within a high-burden West African cohort, followed participants longitudinally through RSV seasons, collecting frequent nasal samples and serial blood draws so that infection events could be identified prospectively rather than reconstructed after the fact. This intensive sampling design allowed the researchers to compare baseline immune profiles, measured before the season or before a documented infection, against subsequent outcomes. When the team stratified participants by their levels of mucosal IgA against stabilized pre-fusion F protein, a clear gradient emerged: individuals with higher pre-existing mucosal pre-F-specific IgA were substantially less likely to acquire RSV infection during follow-up, whereas systemic serum antibody titers, including serum IgG and even serum IgA against the same antigen, showed a far weaker and less consistent relationship with protection.

Technically, the work rests on careful assay design. Mucosal IgA was quantified from nasal secretions normalized to total IgA or to an internal control protein to correct for dilution and collection variability, a persistent methodological problem in mucosal immunology. The antigen used was a stabilized pre-fusion F ectodomain, permitting the investigators to distinguish responses specific to the protective pre-F conformation from responses to the post-fusion form, which dominated older vaccine preparations and natural infection literature alike. By measuring multiple antibody isotypes and subclasses across compartments, and by modeling infection risk with adjustment for age, exposure, prior infection history and season, the analysis could isolate the specific contribution of mucosal pre-F IgA rather than confounding it with general immunological experience accrued over years of viral encounters.

Why should mucosal IgA be so much more predictive than its serum counterpart? The explanation lies in both anatomy and biochemistry. Secretory IgA is actively transported across the epithelial lining by the polymeric immunoglobulin receptor and released into the airway lumen bearing a secretory component that stabilizes the molecule in the protease-rich mucus environment. There, positioned at the exact portal of viral entry, dimeric IgA can cross-link virions, trap them in mucus, block attachment to epithelial receptors and neutralize infection before a single cell is entered. Serum IgG, by contrast, must transude into the airway at concentrations that vary with inflammation and systemic levels, and much of the IgG in blood targets antigenic sites with lower blocking efficiency. In essence, the mucosal antibody pool is the standing army at the border, and the new data show that its size, at least as measured against pre-fusion F, forecasts whether the invasion succeeds.

The epidemiological significance of this finding is difficult to overstate at a moment when RSV prevention strategies are being rolled out globally. Long-acting monoclonal antibodies for infants and maternal vaccination both work by delivering neutralizing antibody, and their demonstrated efficacy already implies that antibody-mediated protection is achievable. But immunogenicity endpoints in trials have leaned heavily on serum neutralization titers, partly because they are easy to measure. The Gambian data suggest that this convention may systematically undervalue candidates or delivery routes that generate mucosal immunity, and overvalue those that produce only transient serum boosts. Intranasal vaccines, live-attenuated candidates and mucosal adjuvants, all of which are in various stages of development for RSV, could find in this study a quantitative surrogate that better reflects their mechanism of action. Conversely, the finding flags the possibility that serum-based correlates may underestimate how quickly immunity wanes at the mucosa even when blood titers look adequate.

There is also a crucial equity dimension embedded in the study’s setting. Much of the historical immunology of RSV has been generated in high-income countries with comparatively low transmission intensity, where infants encounter the virus for the first time in defined seasonal windows. In high-burden settings such as The Gambia, exposure begins earlier, reinfections are frequent, and the immune landscape is sculpted by repeated mucosal encounters with the virus, often alongside other coinfections, malnutrition and environmental stressors. Demonstrating that mucosal pre-F IgA predicts protection in precisely such a context gives the finding immediate relevance for the populations that carry the greatest global RSV mortality, and it validates cohort infrastructure in Africa as an indispensable engine for defining immune correlates that will guide vaccine deployment worldwide.

The study’s implications extend beyond RSV itself. The broader principle it confirms, that protection against pathogens entering through mucosal surfaces is best predicted by antibodies resident at those surfaces, echoes lessons from influenza, SARS-CoV-2 and other respiratory viruses, where intranasal vaccination has generated intense interest precisely because injected vaccines rarely induce robust secretory IgA. For respiratory virus science generally, the result strengthens the argument that mucosal sampling, however logistically demanding, should be incorporated into vaccine trials and correlate-of-protection analyses. It also raises concrete, testable questions for future work: how durable is mucosal pre-F IgA following vaccination or infection, how rapidly it decays relative to serum antibody, whether it can be boosted systemically with high-dose or adjuvanted parenteral vaccines, and whether threshold levels of nasal IgA could ever serve as licensure endpoints.

For the researchers involved, the longitudinal design in a setting of intense natural transmission is what transforms the result from a plausible hypothesis into a predictive correlate. Prospective cohort data of this kind are expensive and operationally complex, requiring teams to track households, sample nasally at frequent intervals, detect infections molecularly even when asymptomatic, and maintain cold chains in challenging field conditions. The reward is a dataset in which the temporal ordering of immune measurement and infection is unambiguous, eliminating recall and survivorship biases that plague cross-sectional serology. It is precisely this architecture that allowed mucosal pre-F-specific IgA to emerge as an independent predictor of protection, holding its ground in multivariable models where serum measures did not.

As RSV vaccines and monoclonals scale up across the world, the field now possesses a sharper instrument for judging them. A measurable, mechanistically sensible correlate of protection, anchored to the viral surface protein that all modern immunogens target and located in the compartment where infection begins, offers vaccine developers a compass needle, regulators a potential benchmark, and immunologists a clearer map of what immunity to RSV actually looks like in the human airway. If subsequent trials confirm and refine this relationship, the measurement of a few microliters of nasal secretion may come to matter as much as the vial of blood that has dominated vaccinology for a century, and the path toward controlling one of the world’s most persistent respiratory pathogens may run, quite literally, through the mucus.